Skip to main content

Biogen Inc.

BIIB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000875045

No open-market purchases or sales by Biogen Inc. insiders were filed in the last 90 days; 1,062 institutions reported holding it in 13F filings for Q3 2026, worth $31.5B in total; Maverick Capital is the only superinvestor holding it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 29, 2026, 1:12 AM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Biogen Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 14, 2026Feb 12, 2025Feb 13, 2024Feb 15, 2023Feb 3, 2022
Revenue$9.89B$9.68B$9.84B$10.2B$11.0B
Cost of revenue$2.40B$2.31B$2.53B$2.28B$2.11B
Research and development$1.78B$2.04B$2.46B$2.23B$2.50B
Selling, general and administrative$2.43B$2.40B$2.55B$2.40B$2.67B
Operating income––––$2.84B
Interest expense$267.5M$250.3M$246.9M$246.6M$253.6M
Income tax$263.6M$273.8M$135.3M$632.8M$52.5M
Net income$1.29B$1.63B$1.16B$3.05B$1.56B
EPS, basic$8.83$11.21$8.02$20.96$10.44
EPS, diluted$8.79$11.18$7.97$20.87$10.40
Weighted shares, basic146.5M145.6M144.7M145.3M149.1M
Weighted shares, diluted147.1M145.9M145.6M146.0M149.6M
Margins and growth
Operating margin––––25.9%
Net margin13.1%16.9%11.8%29.9%14.2%
Revenue growth, year over year+2.2%−1.6%−3.3%−7.4%−18.3%
Net income growth, year over year−20.8%+40.6%−61.9%+95.8%−61.1%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Biogen Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 14, 2026Feb 12, 2025Feb 13, 2024Feb 15, 2023Feb 3, 2022
Accounts receivable$1.34B$1.40B$1.66B$1.71B$1.55B
Inventory$2.17B$2.46B$2.53B$1.34B$1.35B
Total current assets$8.97B$7.46B$6.86B$9.79B$7.86B
Property, plant and equipment$3.06B$3.18B$3.31B$3.30B$3.42B
Goodwill$6.49B$6.48B$6.22B$5.75B$5.76B
Intangible assets$9.18B$9.69B$8.36B$1.85B$2.22B
Total assets$29.4B$28.0B$26.8B$24.6B$23.9B
Accounts payable$432.0M$424.2M$403.3M$491.5M$589.2M
Short-term debt$0$1.75B$150.0M$0$999.1M
Total current liabilities$3.35B$5.53B$3.43B$3.27B$4.30B
Long-term debt$6.29B$6.30B$6.94B$6.28B$6.27B
Total liabilities$11.2B$11.3B$12.0B$11.2B$12.9B
Shareholders' equity$18.3B$16.7B$14.8B$13.4B$11.0B

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Biogen Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 14, 2026Feb 12, 2025Feb 13, 2024Feb 15, 2023Feb 3, 2022
Operating cash flow$2.20B$2.88B$1.55B$1.38B$3.64B
Capital expenditures$153.8M$153.7M$277.0M$240.3M$258.1M
Free cash flow$2.05B$2.72B$1.27B$1.14B$3.38B
Depreciation and amortization$779.9M$673.2M$494.8M$518.4M$487.7M
Stock-based compensation$290.8M$291.2M$264.2M$254.1M$238.6M
Share buybacks–$0$0$750.0M$1.80B
Investing cash flow-$1.37B-$799.2M-$4.10B$1.58B-$563.7M
Financing cash flow-$301.9M-$683.5M$149.3M-$1.75B-$2.09B
Ratio
Stock-based compensation, % of revenue2.9%3.0%2.7%2.5%2.2%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Biogen Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 26, 2026147.8M+0.8%SEC
Jul 27, 2026147.8M+0.8%SEC
Apr 27, 2026147.6M+0.8%SEC
Feb 4, 2026146.8M+0.3%SEC
Oct 29, 2025146.7M+0.7%SEC
Jul 29, 2025146.6M+0.7%SEC
Apr 30, 2025146.5M+0.6%SEC
Feb 11, 2025146.4M+0.7%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.